Ablynx Email Formats

Biotechnology Research • Ghent, Flemish Region, Belgium • 101-200 Employees

Ablynx Email Formats

Ablynx uses 4 email formats. The most common is {first initial}{last name} (e.g., jdoe@ablynx.com), used 48.8% of the time.

Format	Example	Percentage
{first initial}{last name}	jdoe@ablynx.com	48.8%
{first name}{last name}	johndoe@ablynx.com	26.8%
{first initial}.{last name}	j.doe@ablynx.com	19.5%
{last name}{last name}	doedoe@ablynx.com	4.9%

Key Contacts at Ablynx

Marie-Paule Bouche

Associate Director Pharmacology - Regulated Bioanalysis

Sooul Prtector

Ceo

Tim Van Hauwermeiren

Associate Director Business Development

Company overview

Headquarters	Technologiepark 21, Zwijnaarde (Ghent), 9052, BE
Phone number	+3220042025
Websites	ablynx.com sanofi.com
NAICS	541714
SIC	873
Keywords	Discovery, Nanobodies, Research And Drug Development
Employees	101-200
Socials

About Ablynx

Ablynx, a Sanofi company, is engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Nanobodies have potential uses in the treatment of a range of serious and life-threatening human diseases. Ablynx advances a portfolio of Nanobody-based therapeutic programs in several major disease areas, including inflammation, haematology, immuno-oncology and oncology. The acquisition of Ablynx (June 2018) continues Sanofi’s commitment to breakthrough innovation, focused on technologies addressing multiple disease targets with single multi-specific molecules. Sanofi is committed to accelerating Ablynx’s Nanobody development programmes.